Yui Kawasaki

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

Toshio Shimizu, Jacob Sands, Kiyotaka Yoh et al. · Journal of Clinical Oncology · 2023 · 141 citations · Full text

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Aditya Bardia, Ian E. Krop, Takahiro Kogawa et al. · Journal of Clinical Oncology · 2024 · 124 citations · Full text

Criterion validity of the visual estimation method for determining patients' meal intake in a community hospital

Yui Kawasaki, Masashi Sakai, Kazuhiro Nishimura et al. · Clinical Nutrition · 2016 · 62 citations

Food Choice, Nutrition, Body Composition +12

Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Ian E. Krop, Dejan Juric, Toshio Shimizu et al. · Cancer Research · 2022 · 49 citations

Breast Oncology, Immunology, Pathology +21

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

Alexander I. Spira, Aaron Lisberg, Jacob Sands et al. · Journal of Thoracic Oncology · 2021 · 45 citations · Full text

Advanced Nsclc, Medicine, Oa03.03 Datopotamab Deruxtecan +7